Please assess the completion status of the following clinical trial:

Trial Title: Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Chronic HIV-1 infection~3. Antiretroviral treatment with either DRV/r (800/100 mg QD) or LPV/r (400/100 mg BID) monotherapy during at least 6 months prior to screening.~4. Fasting total cholesterol or LDL-cholesterol levels ≥ 200 and ≥130 mg/dL respectively, in the previous two consecutive tests obtained at least 4 weeks apart before screening.~5. Calculated creatinine clearance ≥ 60 mL/min, according to the Cockcroft-Gault formula.~6. Undetectable plasma HIV-1 RNA levels (\< 50 copies/mL) during at least 6 months prior to screening.~7. Adequate treatment adherence.~8. Absence of TDF or FTC resistances.~9. Written informed consent to participate into the study.~Exclusion Criteria:~1. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study~2. Lactating, pregnancy or fertile women willing to be pregnant.~3. Concomitant use of any drug with potential drug-drug interaction with DRV/r, LPV/r or TDF/FTC co-formulation at study entry.~4. Concomitant use of any lipid-lowering drugs at study entry.~5. Prior documented intolerance or hypersensitivity to TDF, FTC, LPV/r or DRV/r.~6. Therapies including interferon, interleukin-2, cytotoxic chemotherapy or immunosuppressors at study entry.~7. Acute or chronic renal documented pathologies.~8. Documented resistance to any of the study drugs (either genotypic or phenotypic)~9. Life expectancy less or equal to 1 year.~10. Current alcohol or substance use judged by the investigator to potentially interfere with subject study compliance.~11. Subjects currently taking part in any other clinical trial using an investigational product, with the exception of studies where the treatment studied have stopped for more than 12 weeks.~12. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TDF/FTC (3 months) + Placebo (6 months) (Type: EXPERIMENTAL): TDF/FTC (3 months) + Placebo (6 months)
- Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months) (Type: PLACEBO_COMPARATOR): Placebo (3 months) + TDF/FTC (3 months) + Placebo (3 months)

Based on this trial design, predict the completion outcome and termination type (if applicable).